Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan Pub Date : 2023-06-01 DOI:10.19852/j.cnki.jtcm.20230208.002

Chen Wenlin, Liang Fang, Zhang Yuncheng, L V Jinzhen, Yang Daguo

{"title":"Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.","authors":"Chen Wenlin, Liang Fang, Zhang Yuncheng, L V Jinzhen, Yang Daguo","doi":"10.19852/j.cnki.jtcm.20230208.002","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effects of Zhenggan Huayu decoction (, ZGHY) combined with entecavir (ETV) on the gut microbiota in patients with chronic hepatitis B (CHB) fibrosis.Methods: A total of 59 CHB-related fibrosis patients were enrolled and treated with ZGHY combined with ETV (ZGHY + ETV) and ETV alone. Fecal samples were collected from patients at weeks 0, 12, and 24 after treatment and gut microbiota were analyzed by 16S rRNA gene sequencing.Results: Compared to the ETV group, microbiota diversity in the ZGHY + ETV group was increased after 24 weeks. Some potentially pathogenic bacteria, including spp., spp., and spp. were reduced in the ZGHY + ETV group, while spp., spp., and several other beneficial bacteria were increased.Conclusion: Decreases in pathogenic bacteria and increases in probiotics were not always observed in the Traditional Chinese Medicine (TCM) group (e.g., was abundant). As an adjuvant TCM formulation for ETV, ZGHY had a positive role in the treatment of CHB patients.","PeriodicalId":17450,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"43 3","pages":"559-567"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133949/pdf/JTCM-43-3-559.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19852/j.cnki.jtcm.20230208.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the effects of Zhenggan Huayu decoction (, ZGHY) combined with entecavir (ETV) on the gut microbiota in patients with chronic hepatitis B (CHB) fibrosis.

Methods: A total of 59 CHB-related fibrosis patients were enrolled and treated with ZGHY combined with ETV (ZGHY + ETV) and ETV alone. Fecal samples were collected from patients at weeks 0, 12, and 24 after treatment and gut microbiota were analyzed by 16S rRNA gene sequencing.

Results: Compared to the ETV group, microbiota diversity in the ZGHY + ETV group was increased after 24 weeks. Some potentially pathogenic bacteria, including spp., spp., and spp. were reduced in the ZGHY + ETV group, while spp., spp., and several other beneficial bacteria were increased.

Conclusion: Decreases in pathogenic bacteria and increases in probiotics were not always observed in the Traditional Chinese Medicine (TCM) group (e.g., was abundant). As an adjuvant TCM formulation for ETV, ZGHY had a positive role in the treatment of CHB patients.

查看原文本刊更多论文

正肝化瘀汤联合恩替卡韦对慢性乙型肝炎纤维化患者肠道菌群的影响。

目的:探讨正肝化瘀汤联合恩替卡韦(ETV)对慢性乙型肝炎(CHB)纤维化患者肠道菌群的影响。方法:共入组59例chb相关纤维化患者，采用ZGHY联合ETV (ZGHY + ETV)和ETV单独治疗。于治疗后第0、12和24周采集患者粪便样本，并通过16S rRNA基因测序分析肠道微生物群。结果:与ETV组相比，24周后ZGHY + ETV组微生物群多样性增加。ZGHY + ETV组一些潜在致病菌，包括spp.、spp.和spp.减少，而spp.、spp.和其他几种有益菌增加。结论:中药组病原菌数量减少，益生菌数量增加的现象并不普遍(如大量)。ZGHY作为ETV的辅助中药制剂，对慢性乙型肝炎患者有积极的治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

自引率

0.00%

发文量